Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niacin versus placebo for cardiovascular risk indices in women with polycystic ovary syndrome
ISRCTN37787683Phase 4Completed
- Sponsor
- Hull University Teaching Hospitals
- Start
- Apr 2010
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of laropiprant in polycystic ovary syndrome (PCOS), sponsored by Hull University Teaching Hospitals. Started Apr 2010; status: completed.
02
Drugs
laropiprant
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on ISRCTN37787683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN37787683.